Guardian Capital Advisors LP grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 2.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,015 shares of the company’s stock after purchasing an additional 1,905 shares during the quarter. Guardian Capital Advisors LP’s holdings in Novo Nordisk A/S were worth $3,640,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in NVO. Geode Capital Management LLC grew its position in shares of Novo Nordisk A/S by 20.6% in the first quarter. Geode Capital Management LLC now owns 28,778 shares of the company’s stock valued at $985,000 after purchasing an additional 4,910 shares during the last quarter. Sei Investments Co. lifted its stake in shares of Novo Nordisk A/S by 79.2% during the second quarter. Sei Investments Co. now owns 17,151 shares of the company’s stock valued at $736,000 after buying an additional 7,578 shares during the period. TD Asset Management Inc. lifted its stake in shares of Novo Nordisk A/S by 49.2% during the second quarter. TD Asset Management Inc. now owns 64,170 shares of the company’s stock valued at $2,752,000 after buying an additional 21,157 shares during the period. Tirschwell & Loewy Inc. lifted its stake in shares of Novo Nordisk A/S by 0.9% during the second quarter. Tirschwell & Loewy Inc. now owns 409,920 shares of the company’s stock valued at $17,581,000 after buying an additional 3,725 shares during the period. Finally, Trillium Asset Management LLC lifted its stake in shares of Novo Nordisk A/S by 0.4% during the second quarter. Trillium Asset Management LLC now owns 11,928 shares of the company’s stock valued at $512,000 after buying an additional 48 shares during the period. Institutional investors and hedge funds own 6.18% of the company’s stock.

Novo Nordisk A/S (NVO) traded up $0.29 during trading hours on Tuesday, reaching $52.42. 1,027,100 shares of the company’s stock were exchanged, compared to its average volume of 2,084,545. The stock has a market capitalization of $132,931.50, a P/E ratio of 22.76, a P/E/G ratio of 3.07 and a beta of 0.63. Novo Nordisk A/S has a 12 month low of $32.83 and a 12 month high of $52.60.

Several equities analysts recently issued reports on the stock. Morgan Stanley raised shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Friday, December 1st. Bank of America raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, December 6th. BNP Paribas downgraded shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research note on Monday, September 25th. Finally, Zacks Investment Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a research note on Tuesday, October 10th. Three analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $55.00.

In related news, insider Eric S. Sprott purchased 50,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were bought at an average price of $8.34 per share, with a total value of $417,000.00.

COPYRIGHT VIOLATION NOTICE: “Guardian Capital Advisors LP Grows Stake in Novo Nordisk A/S (NVO)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/12/guardian-capital-advisors-lp-grows-stake-in-novo-nordisk-as-nvo.html.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.